Related references
Note: Only part of the references are listed.Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus
James Bentham et al.
NATURE GENETICS (2015)
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R. A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?
Zana Brkic et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare
Melissa E. Munroe et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort
M. B. Urowitz et al.
ARTHRITIS CARE & RESEARCH (2012)
The genetics of systemic lupus erythematosus and implications for targeted therapy
Andrea L. Sestak et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus
Rachel Klein et al.
ARCHIVES OF DERMATOLOGY (2011)
B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels
Lauren L. Ritterhouse et al.
ARTHRITIS AND RHEUMATISM (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus
Sebastian Dolff et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Neutralization of Interferon-alpha/beta-Inducible Genes and Downstream Effect in a Phase I Trial of an Anti-Interferon-alpha Monoclonal Antibody in Systemic Lupus Erythematosus
Yihong Yao et al.
ARTHRITIS AND RHEUMATISM (2009)
CONNECTIVE TISSUE DISEASES What does the death of Riquent™ hold for the future of SLE?
Joan T. Merrill et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity
Chee-Seng Yee et al.
RHEUMATOLOGY (2009)
Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus
Murray B. Urowitz et al.
JOURNAL OF RHEUMATOLOGY (2008)
Mechanisms of disease: Systemic lupus erythematosus
Anisur Rahman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Combined oral contraceptives in women with systemic lupus erythematosus
M Petri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus
J Albrecht et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus:: A randomized trial
JP Buyon et al.
ANNALS OF INTERNAL MEDICINE (2005)
The role of APRIL and BAFF in lymphocyte activation
P Schneider
CURRENT OPINION IN IMMUNOLOGY (2005)
Clusters of clinical and immunologic features in systemic lupus erythematosus:: Analysis of 600 patients from a single center
J Font et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2004)
Challenges in bringing the bench to bedside in drug development for SLE
JT Merrill et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Share Paper
